Search Login Register

Sirolimus (Rapamycin) Summary

Description: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

Also Known As: Rapamycin; Rapamune; AY 22-989; I-2190A; Wyeth Brand of Sirolimus; AY 22 989; AY 22989; I 2190A; I2190A

Networked: 7416 relevant articles (578 outcomes, 1223 trials/studies) for this Drug

Key Diseases for which Sirolimus is Relevant

  1. Neoplasms (Cancer) : 108 outcomes 216 studies in 1690 results
  2. Renal Cell Carcinoma (Grawitz Tumor) : 22 outcomes 24 studies in 187 results
  3. Myocardial Infarction : 21 outcomes 78 studies in 195 results
  4. Hyperplasia : 20 outcomes 34 studies in 145 results
  5. Tuberous Sclerosis (Bourneville's Disease) : 19 outcomes 37 studies in 314 results
Show All >>

Drugs Related to Sirolimus

  1. everolimus
  2. Calcineurin
  3. Sirolimus (Rapamycin)
  4. Paclitaxel (Taxol)
  5. temsirolimus
  6. Phosphotransferases (Kinase)
  7. Cyclosporine (Ciclosporin)
  8. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
  9. Tacrolimus (Prograf)
  10. Polymers
Show All >>

Therapies Related to Sirolimus

  1. Stents
  2. Transplants (Transplant)
  3. Transplantation (Transplant Recipients)
  4. Heterologous Transplantation (Xenotransplantation)
  5. Homologous Transplantation (Allograft)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.